Impact of pharmaceutical cocrystals: the effects on drug pharmacokinetics

Bibliography

• Tozer TN, Rowland M. Introduction to pharmacokinetics and pharmacodynamics: the quantitative basis of drug therapy. Lippincott Williams and Wilkins; Baltimore, MD: 2006
   Google Scholar
• Allen LV, Popovich NG, Ansel HC. Ansel’s pharmaceutical dosage forms and drug delivery systems. Lippincott Williams and Wilkins, Baltimore, MD; 2005
   Google Scholar
• The United State FDA. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. 2000
   Google Scholar
• The United State FDA. Guidance for submitting supporting documentation in drug applications for the manufacture of drug substances. 1987
   Google Scholar
• Amidon GL, Lennernäs H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-20
   PubMed Web of Science ®Google Scholar
• Thayer AM. Finding solutions. Chem Eng News 2010;88:13
   Web of Science ®Google Scholar
• Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res 2004;21:201-30
   PubMed Web of Science ®Google Scholar
• Vippagunta SR, Brittain HG, Grant DJW. Crystalline solids. Adv Drug Deliv Rev 2001;48:3-26
   PubMed Web of Science ®Google Scholar
• Datta S, Grant DJW. Crystal structures of drugs: advances in determination, prediction and engineering. Nat Rev Drug Discov 2004;3:42-57
   PubMed Web of Science ®Google Scholar
• Byrn SR, Pfeiffer RR, Ganey M, et al. Pharmaceutical solids: a strategic approach to regulatory considerations. Pharm Res 1995;12:945-54
   PubMed Web of Science ®Google Scholar
• Byrn SR, Pfeiffer RR, Stowell JG. Solid-state chemistry of drugs. 2nd edition. SSCI, Inc; West Lafayette, Indiana: 1999
   Google Scholar
• Hancock B, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 1997;86:1-12
   PubMed Web of Science ®Google Scholar
• Bauer J, Spanton S, Henry R, et al. Ritonavir: an extraordinary example of conformational polymorphism. Pharm Res 2001;18:859-66
   PubMed Web of Science ®Google Scholar
• Qiu Y, Chen Y, Zhang GGZ, editor. Developing solid oral dosage forms: pharmaceutical theory and practice. Y, Chen Y, Zhang GGZ, Liu L., Porter WR 1st edition. Elsevier; Burlington, MA: 2009
   Google Scholar
• Gould PL. Salt selection for basic drugs. Int J Pharm 1986;33:201-17
   Web of Science ®Google Scholar
• Hickey MB, Peterson ML, Manas ES, et al. Hydrates and solid-state reactivity: a survey of beta-lactam antibiotics. J Pharm Sci 2007;96:1090-9
   PubMed Web of Science ®Google Scholar
• Lutker KM, Quinones R, Xu J, et al. Polymorphs and hydrates of acyclovir. J Pharm Sci 2011;100:949-63
   PubMed Web of Science ®Google Scholar
• Peterson ML, Collier EA, Hickey MB, et al. Multi-component pharmaceutical crystalline phases: engineering for performance. In: Tiekink ERT, Vittal J, Zaworotko MJ, editors. Organic crystal engineering: frontiers in crystal engineering. John Wiley & Sons Ltd, Chichester, West Sussex, UK; 2010
   Google Scholar
• Van Gyseghema E, Stokbroekxb S, de Armasb HN, et al. Solid state characterization of the anti-HIV drug TMC114: interconversion of amorphous TMC114, TMC114 ethanolate and hydrate. Eur J Pharm Sci 2009;38:489-97
   PubMed Web of Science ®Google Scholar
• Bundgaard H, Jensen E, Falch E. Water-soluble, solution-stable, and biolabile N -substituted (Aminomethyl)benzoate ester prodrugs of acyclovir. Pharm Res 1991;8:1087-93
   PubMed Web of Science ®Google Scholar
• Stahl PH, Wermuth CG. Handbook of pharmaceutical salts: properties, selection, and use. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim; 2002
   Google Scholar
• Berge SM, Bighley LD, Monkhouse DC. Pharmaceutical salts. J Pharm Sci 1977;66:1-19
   PubMed Web of Science ®Google Scholar
• Vishweshwar P, McMahon JA, Bis JA, et al. Pharmaceutical co-crystals. J Pharm Sci 2006;95:499-516
   PubMed Web of Science ®Google Scholar
• Editorial. Amidopyrine and the barbiturates as possible causes of granulocytopenia. Can Med Assoc J 1934;30:538-40
   PubMedGoogle Scholar
• Aitipamula S, Banerjee R, Bansal AK, et al. Polymorphs, salts, and cocrystals: what’s in a name? Cryst Growth Des 2012;12:2147-52
   Web of Science ®Google Scholar
• Huang KS, Britton D, Etter MC, et al. A novel class of phenol–pyridine co-crystals for second harmonic generation. J Mater Chem 1997;7:713-20
   Web of Science ®Google Scholar
• Cheney ML, Weyna DR, Shan N, et al. Supramolecular architectures of meloxicam carboxylic acid cocrystals, a crystal engineering case study. Cryst Growth Des 2010;10:4401-13
   Web of Science ®Google Scholar
• Shan N, Zaworotko MJ. The role of cocrystals in pharmaceutical science. Drug Discov Today 2008;13:440-6
   PubMed Web of Science ®Google Scholar
• Almarsson O, Zaworotko MJ. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical cocrystals represent a new path to improved medicines? Chem Commun (Camb) 2004;1889-96
   PubMed Web of Science ®Google Scholar
• The United State FDA. Guidance for industry: regulatory classification of pharmaceutical co-crystals. 2013
   Google Scholar
• Smith AJ, Kim SH, Duggirala NK, et al. Improving lithium therapeutics by crystal engineering of novel ionic cocrystals. Mol Pharm 2013;10:4728-38
   PubMedGoogle Scholar
• Bardwell DA, Adjiman CS, Arnautova YA, et al. Towards crystal structure prediction of complex organic compounds - a report on the fifth blind test. Acta Crystallogr B 2011;67:535-51
   PubMed Web of Science ®Google Scholar
• Chan HCS, Kendrick J, Neumann MA, et al. Towards ab initio screening of co-crystal formation through lattice energy calculations and crystal structure prediction of nicotinamide, isonicotinamide, picolinamide and paracetamol multi-component crystals. CrystEngComm 2013;15:3799-807
   Web of Science ®Google Scholar
• Morissette SL, Almarsson O, Peterson ML, et al. High-throughput crystallization: polymorphs, salts, cocrystals and solvates of pharmaceutical solids. Adv Drug Deliv Rev 2004;56:275-300
   PubMed Web of Science ®Google Scholar
• Desiraju GR. Crystal engineering: the design of organic solids. Elsevier, Amsterdam; 1989
   Google Scholar
• Desiraju GR. Supramolecular synthons in crystal engineering - a new organic-synthesis. Angew Chem Int Ed 1995;34:2311-27
   Web of Science ®Google Scholar
• Desiraju GR. Hydration in organic crystals: prediction from molecular structure. J Chem Soc Chem Commun 1991;426-8
   Google Scholar
• Infantes L, Fabian L, Motherwell WDS. Organic crystal hydrates: what are the important factors for formation. CrystEngComm 2007;9:65-71
   Web of Science ®Google Scholar
• Weyna DR, Shattock T, Vishweshwar P, et al. Synthesis and structural characterization of cocrystals and pharmaceutical cocrystals: mechanochemistry vs slow evaporation from solution. Cryst Growth Des 2009;9:1106-23
   Web of Science ®Google Scholar
• Trask A, Jones W. Crystal engineering of organic cocrystals by the solid-state grinding approach. In: Toda F, editor. Organic solid state reactions. Springer; Berlin, Heidelberg: 2005. p. 41-70
   Google Scholar
• Shan N, Jones W. A green chemistry approach to the synthesis of a crystalline organic inclusion compound. Green Chem 2003;5:728-30
   Web of Science ®Google Scholar
• Shan N, Toda F, Jones W. Mechanochemistry and co-crystal formation: effect of solvent on reaction kinetics. Chem Commun (Camb) 2002;2372-3
   PubMed Web of Science ®Google Scholar
• Medina C, Daurio D, Nagapudi K, et al. Manufacture of pharmaceutical co-crystals using twin screw extrusion: a solvent-less and scalable process. J Pharm Sci 2009;99:1693-6
   Web of Science ®Google Scholar
• Pagire S, Korde S, Ambardekar R, et al. Microwave assisted synthesis of caffeine/maleic acid co-crystals: the role of the dielectric and physicochemical properties of the solvent. CrystEngComm 2013;15:3705-10
   Web of Science ®Google Scholar
• am Ende DJ, Anderson SR, Salan JS. Development and scale-up of cocrystals using resonant acoustic mixing. Org Process Res Dev 2014;18:331-41
   Web of Science ®Google Scholar
• Pudipeddi M, Serajuddin ATM. Trends in solubility of polymorphs. J Pharm Sci 2005;94:929-39
   PubMed Web of Science ®Google Scholar
• Childs SL, Chyall LJ, Dunlap JT, et al. Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. J Am Chem Soc 2004;126:13335-42
   PubMed Web of Science ®Google Scholar
• Rong L. Water-insoluble drug formulation. 2nd Edition. CRC Press, Boca Raton, Florida, USA; 2008
   Google Scholar
• Li ZJ, Abramov Y, Bordner J, et al. Solid-state acid-base interactions in complexes of heterocyclic bases with dicarboxylic acids: crystallography, hydrogen bond analysis, and 15N NMR spectroscopy. J Am Chem Soc 2006;128:8199-210
   PubMed Web of Science ®Google Scholar
• Smith AJ, Kavuru P, Wojtas L, et al. Cocrystals of quercetin with improved solubility and oral bioavailability. Mol Pharm 2011;8:1867-76
   PubMed Web of Science ®Google Scholar
• Aakeroy CB, Forbes S, Desper J. Using cocrystals to systematically modulate aqueous solubility and melting behavior of an anticancer drug. J Am Chem Soc 2009;131:17048-9
   PubMed Web of Science ®Google Scholar
• Bak A, Gore A, Yanez E, et al. The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics. J Pharm Sci 2008;97:3942-56
   PubMed Web of Science ®Google Scholar
• Lin Y, Yang H, Yang C, et al. Preparation, characterization, and evaluation of dipfluzine–benzoic acid co-crystals with improved physicochemical properties. Pharm Res 2014;31:566-78
   PubMed Web of Science ®Google Scholar
• Huang Y, Zhang B, Gao Y, et al. Baicalein–nicotinamide cocrystal with enhanced solubility, dissolution, and oral bioavailability. J Pharm Sci 2014; Advanced paper; doi: 10.1002/jps.24048
   Web of Science ®Google Scholar
• Good DJ, Rodriguez-Hornedo N. Solubility advantage of pharmaceutical cocrystals. Cryst Growth Des 2009;9:2252-64
   Web of Science ®Google Scholar
• Thakuriaa R, Deloria A, Jones W, et al. Pharmaceutical cocrystals and poorly soluble drugs. Int J Pharm 2013;453:101-25
   PubMedGoogle Scholar
• Weyna DR, Cheney ML, Shan N, et al. Improving solubility and pharmacokinetics of meloxicam via multiple-component crystal formation. Mol Pharm 2012;9:2094-102
   PubMedGoogle Scholar
• Stanton MK, Kelly RC, Colletti A, et al. Improved pharmacokinetics of AMG 517 through co-crystallization part 2: analysis of 12 carboxylic acid co-crystals. J Pharm Sci 2011;100:2734-43
   PubMed Web of Science ®Google Scholar
• Almarsson O, Peterson ML, Zaworotko MJ. The A to Z of pharmaceutical cocrystals: a decade of fast-moving new science and patents. Pharm Pat Anal 2012;1:313-27
   PubMedGoogle Scholar
• Stanton MK, Bak A. Physicochemical properties of pharmaceutical co-crystals: a case study of ten AMG 517 co-crystals. Cryst Growth Des 2008;8:3856-62
   Web of Science ®Google Scholar
• Stanton MK, Kelly RC, Colletti A, et al. Improved pharmacokinetics of AMG 517 through co-crystallization part 1: comparison of two acids with corresponding amide co-crystals. J Pharm Sci 2010;99:3769-78
   PubMed Web of Science ®Google Scholar
• The United States FDA Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations
   Google Scholar
• The United States FDA Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations
   Google Scholar
• The ICH Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals Finalised Guideline (M3)
   Google Scholar
• Takagi T, Ramachandran C, Bermejo M, et al. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm 2006;3:631-43
   PubMed Web of Science ®Google Scholar
• Dahan A, Miller JM, Amidon GL. Prediction of solubility and permeability class membership: provisional BCS classification of the world’s top oral drugs. AAPS J 2009;11:740-6
   PubMed Web of Science ®Google Scholar
• Machatha S, Yalkowsky SH. Comparison of the octanol/water partition coefficients calculated by ClogP, ACDlogP and KowWin to experimentally determined values. Int J Pharm 2005;294:185-92
   PubMed Web of Science ®Google Scholar
• Martinez MN, Fahmy R. The scientific basis for establishing solubility criteria for veterinary species. J Vet Pharmacol Ther 2012;35(Suppl 1):81-6
   PubMedGoogle Scholar
• The United States FDA Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers
   Google Scholar
• Jung MS, Kim JS, Kim MS, et al. Bioavailability of indomethacin-saccharin cocrystals. J Pharm Pharmacol 2010;62:1560-8
   PubMed Web of Science ®Google Scholar
• Keene ON. The log transformation is special. Stat Med 1995;14:818-19
   Google Scholar
• McNamara DP, Childs SL, Giordano J, et al. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm Res 2006;23:1888-97
   PubMed Web of Science ®Google Scholar
• Wang HY, Johnson GP, Friedman E. Lithium treatment inhibits protein kinase C translocation in rat brain cortex. Psychopharmacology (Berl) 2001;158:80-6
   PubMed Web of Science ®Google Scholar
• See The FDA Summary Basis of Approval for Lithium Carbonate Oral Capsule (NDA #017812)
   Google Scholar
• Lippmann S, Evans R. A comparison of three types of lithium release preparations. Hosp Community Psychiatry 1983;34:113-14
   PubMedGoogle Scholar
• Cheney ML, Weyna DR, Shan N, et al. Coformer selection in pharmaceutical cocrystal development: a case study of a meloxicam aspirin cocrystal that exhibits enhanced solubility and pharmacokinetics. J Pharm Sci 2011;100:2172-81
   PubMed Web of Science ®Google Scholar
• Puschner B, Poppenga RH, Lowenstine LJ, et al. Assessment of melamine and cyanuric acid toxicity in cats. J Vet Diagn Invest 2007;19:616-24
   PubMed Web of Science ®Google Scholar
• Sáez-Plaza P, Michałowski T, Navas MJ, et al. An overview of the kjeldahl method of nitrogen determination. Part I. Early history, chemistry of the procedure, and titrimetric Finish. Crit Rev Anal Chem 2013;43:178-223
   Web of Science ®Google Scholar
• Hau AK, Kwan TH, Li PK. Melamine toxicity and the kidney. J Am Soc Nephrol 2009;20:245-50
   PubMed Web of Science ®Google Scholar
• WHO Report on Melamine and Cyanuric acid: Toxicity, Preliminary Risk Assessment and Guidance on Levels in Food
   Google Scholar
• Hammond BG, Barbee SJ, Inoue T, et al. A review of toxicology studies on cyanurate and its chlorinated derivatives. Environ Health Perspect 1986;69:287-92
   PubMed Web of Science ®Google Scholar
• The United States FDA Guidance for Industry: Pharmaceutical Components at Risk for Melamine Contamination
   Google Scholar
• Smith AJ, Kavuru P, Arora KK, et al. Crystal engineering of green tea epigallocatechin-3-gallate (EGCg) cocrystals and pharmacokinetic modulation in rats. Mol Pharm 2013;10:2948-61
   PubMed Web of Science ®Google Scholar
• Remenar JF, Morissette SL, Peterson ML, et al. Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. J Am Chem Soc 2003;125:8456-7
   PubMed Web of Science ®Google Scholar
• Fleischman SG, Kuduva SS, McMahon JA, et al. Crystal engineering of the composition of pharmaceutical phases: multiple-component crystalline solids involving carbamazepine. Cryst Growth Des 2003;3:909-19
   Web of Science ®Google Scholar
• Walsh RDB, Bradner MW, Fleischman SG, et al. Crystal engineering of the composition of pharmaceutical phases. Chem Commun (Camb) 2003;186-7
   PubMed Web of Science ®Google Scholar
• Ranzani LS, Aldea AF. Pharmaceutical compositions of co-crystals of tramadol and coxibs. WO2011/151080A1; 2011
   Google Scholar
• Holland J, Frampton C, Chorlton A, et al. Cilostazol cocrystals and compositions. WO2011/158110A2; 2011
   Google Scholar
• Childs SL, Kandi P, Lingireddy SR. Formulation of a danazol cocrystal with controlled supersaturation plays an essential role in improving bioavailability. Mol Pharm 2013;10:3112-27
   PubMed Web of Science ®Google Scholar
• Zhang T, Yang Y, Wang H, et al. Using dissolution and pharmacokinetics studies of crystal form to optimize the original iloperidone. Cryst Growth Des 2013;13:5261-6
   Web of Science ®Google Scholar
• Zhang T, Wang H, Jia J, et al. Syntheses and pharmacokinetics properties of an iloperidone pharmaceutical cocrystal. Inorg Chem Commun 2014;39:144-6
   Web of Science ®Google Scholar
• Remenar J, MacPhee JM, Peterson ML, et al. Novel crystalline forms of conazoles and methods of making and using the same. WO2005/092884A1; 2005
   Google Scholar
• Variankaval N, Wenslow R, Murry J, et al. Preparation and solid-state characterization of nonstoichiometric cocrystals off a phosphodiesterase-IV inhibitor annul L-tartaric acid. Cryst Growth Des 2006;6:690-700
   Web of Science ®Google Scholar
• Cheney ML, Shan N, Healey ER, et al. Effects of crystal form on solubility and pharmacokinetics: a crystal engineering case study of lamotrigine. Cryst Growth Des 2010;10:394-405
   Web of Science ®Google Scholar
• Smith AJ, Kim JS, Tan J, et al. Plasma and brain pharmacokinetics of previously unexplored lithium salts. RSC Adv 2014;4:12362-5
   Google Scholar
• Hanna M, Shan N, Cheney MC, et al. In vivo studies of crystalline forms of meloxicam. US8389512B2; 2013
   Google Scholar
• Holland J, Frampton C, Chorlton A, et al. Metaxalone cocrystals. US2013/0158083A1; 2013
   Google Scholar
• Peterson ML, Hickey MB, Oliveira M, et al. Modafinil compositions. US2005267209A1; 2005
   Google Scholar
• Bauer VJ, O’Neill MH, Kidon BJ, et al. (Pyrroloquinoxalinyl) pyrazinecarbohydrazide-oxalic acid co-crystal for treatment of cancer and other diseases. US8058437B2; 2011
   Google Scholar
• Hayashi M, Tomita M. Mechanistic analysis for drug permeation through intestinal membrane. Drug Metab Pharmacokinet 2007;22:67-77
   PubMed Web of Science ®Google Scholar